MetaCap

Apnimed (APMD) vs Nuvectis Pharma (NVCT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Apnimed is the larger company by market cap ($669.8 million vs $666.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

APMD-35.64%NVCT-9.90%
+34%-7%-47%
Jul 31, 20261 yearNov 20, 2026
APMD-35.64%NVCT-9.90%
+30%-6%-43%
Jul 27, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

APMD versus NVCT key metrics
MetricAPMDNVCT
Share price$16.09$19.39
Market cap$669.84M$666.80M
1-day change-6.70%-2.27%
YTD return—+156.82%
1-year return—+218.91%
P/E ratio (TTM)1.21—
EPS (TTM)$13.34$-2.00
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-26.44M
52-week high$35.29$29.28
52-week low$13.88$5.77
Distance from 52-week high-54.41%-33.77%
Analyst consensusstrong_buynone
Avg. price target upside+210.75%+82.57%
Average volume458.58K206.37K
Shares outstanding41.63M34.39M
Employees11219
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Apnimed

APMD stock →

Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets.

Health Care · Biotechnology: Pharmaceutical Preparations · 112 employees

About Nuvectis Pharma

NVCT stock →

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees

APMD vs NVCT FAQ

Which is bigger, Apnimed or Nuvectis Pharma?

Apnimed (APMD) is larger, with a market capitalization of $669.84M compared with $666.80M for Nuvectis Pharma (NVCT).

Are Apnimed and Nuvectis Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons